Skip to main content
. 2020 Oct 30;11:584770. doi: 10.3389/fphar.2020.584770

FIGURE 4.

FIGURE 4

YZT reduces the pathological phospho tau in P301S and 3XTg-AD mice models. (A) Regular YZT treatment decreased the sarcosyl insoluble tau protein levels in the brain homogenates of P301S tau mice. There was no change in the soluble tau in the sarcosyl soluble brain homogenate fraction. (B) The quantified results of different tau epitopes protein levels in brain lysates of P301S tau mice was performed using Image J software. (C) Long term YZT treatment lowered the sarcosyl insoluble phospho tau protein levels in the brain homogenates of 3XTg-AD mice model. There was no change in the soluble tau in the sarcosyl soluble brain homogenate fraction. (D) The densitometric analysis of the various tau epitopes protein levels in the brain lysates of 3XTg-AD mice models was performed using Image J software. **p < 0.01; ***p < 0.001.